Risk of cancer in children exposed to didanosine in utero.

Date publication

mai 2016

Journal

AIDS (London, England)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr JANNIER Sarah

Tous les auteurs :
Hleyhel M, Goujon S, Delteil C, Vasiljevic A, Luzi S, Stephan JL, Reliquet V, Jannier S, Tubiana R, Dollfus C, Faye A, Mandelbrot L, Clavel J, Warszawski J, Blanche S,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26854809

Résumé

Evaluation of long-term tolerance to antiretroviral exposure during pregnancy is required. An increased risk of cancer has been suggested in children exposed in utero to didanosine.

Mots clés

Adolescent, Anti-HIV Agents, adverse effects, Child, Child, Preschool, Didanosine, adverse effects, Female, France, epidemiology, HIV Infections, drug therapy, Humans, Incidence, Infant, Infant, Newborn, Maternal-Fetal Exchange, Neoplasms, epidemiology, Pregnancy, Pregnancy Complications, Infectious, drug therapy, Prenatal Exposure Delayed Effects, epidemiology, Prospective Studies, Risk Assessment, Surveys and Questionnaires

Référence

AIDS. 2016 05 15;30(8):1245-56